Passa al contenuto
Merck

Novel hypoglycemic injury mechanism: N-methyl-D-aspartate receptor-mediated white matter damage.

Annals of neurology (2013-11-19)
Xin Yang, Margaret A Hamner, Angus M Brown, Richard D Evans, Zu-Cheng Ye, Shengdi Chen, Bruce R Ransom
ABSTRACT

Hypoglycemia is a common adverse event and can injure central nervous system (CNS) white matter (WM). We determined whether glutamate receptors were involved in hypoglycemic WM injury. Mouse optic nerves (MON), CNS WM tracts, were maintained at 37°C with oxygenated artificial cerebrospinal fluid (ACSF) containing 10mM glucose. Aglycemia was produced by switching to 0 glucose ACSF. Supramaximal compound action potentials (CAPs) were elicited using suction electrodes, and axon function was quantified as the area under the CAP. Amino acid release was measured using high-performance liquid chromatography. Extracellular lactate concentration ([lactate(-)]o) was measured using an enzyme electrode. About 50% of MON axons were injured after 60 minutes of aglycemia (90% after 90 minutes); injury extent was not affected by animal age. Blockade of N-methyl-D-aspartate (NMDA)-type glutamate receptors improved recovery after 90 minutes of aglycemia by 250%. Aglycemic injury was increased by reducing [Mg(2+)]o or increasing [glycine]o , and decreased by lowering pHo , expected results for NMDA receptor-mediated injury. pHo increased during aglycemia due to a drop in [lactate(-)]o. Aglycemic injury was dramatically reduced in the absence of [Ca(2+)]o. Extracellular aspartate, a selective NMDA receptor agonist, increased during aglycemia ([glutamate]o fell). Aglycemia injured WM by a unique excitotoxic mechanism involving NMDA receptors (located primarily on oligodendrocytes). During WM aglycemia, the selective NMDA agonist aspartate is released, probably from astrocytes. Injury is mediated by Ca(2+) influx through aspartate-activated NMDA receptors made permeable by an accompanying alkaline shift in pHo caused by a fall in [lactate(-)]o. These insights have important clinical implications.

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Sigma-Aldrich
Glicina, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Glicina, suitable for electrophoresis, ≥99%
Sigma-Aldrich
L-Aspartic acid, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
Glicina, BioUltra, Molecular Biology, ≥99.0% (NT)
Sigma-Aldrich
Glicina, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
Sigma-Aldrich
Kynurenic acid, ≥98%
Sigma-Aldrich
Glycine hydrochloride, ≥99% (HPLC)
SAFC
Glicina
Sigma-Aldrich
Glicogeno, ≥75% dry basis
Sigma-Aldrich
L-Aspartic acid, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Glycogen from bovine liver, ≥85% dry basis (enzymatic)
Supelco
Glicina, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glicina, BioXtra, ≥99% (titration)
Sigma-Aldrich
Glicina, ACS reagent, ≥98.5%
Sigma-Aldrich
L-Aspartic acid, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
Glycogen from mussel, Mytilus genus, for DNA precipitations
Sigma-Aldrich
DL-Aspartic acid, ≥99% (TLC)
Sigma-Aldrich
Glicina, 99%, FCC
Sigma-Aldrich
L-Aspartic acid, BioUltra, ≥99.5% (T)
Sigma-Aldrich
Glicina, meets analytical specification of Ph. Eur., BP, USP, 99-101% (based on anhydrous substance)
USP
Glicina, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
L-Aspartic acid potassium salt, ≥98% (HPLC)
SAFC
L-Aspartic acid
Sigma-Aldrich
Glicina, puriss. p.a., reag. Ph. Eur., buffer substance, 99.7-101% (calc. to the dried substance)
Sigma-Aldrich
Glycine 1 M solution
Supelco
L-Aspartic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glycogen from rabbit liver, ≥85% dry basis (enzymatic)
Aspartic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
NBQX disodium salt hydrate, ≥98% (HPLC)
Sigma-Aldrich
Glycogen from mussel, Mytilus genus, ≥85% anhydrous basis (enzymatic)